TOday’s Movers: Xenon (NASDAQ:XENE) Stock Rating Reiterated at Jefferies; $5.0 Target Price Indicates 58.73 % Potential

September 17, 2017 - By Vivian Park

 TOday’s Movers: Xenon (NASDAQ:XENE) Stock Rating Reiterated at Jefferies; $5.0 Target Price Indicates 58.73 % Potential

Xenon (NASDAQ:XENE) Rating Reaffirmed

Jefferies now has a $5.0 TP on the $56.70 million market cap company or 58.73 % upside potential. In a note revealed on 11 September, Xenon (NASDAQ:XENE) shares have had their “Buy” Rating reiterated by research professionals at Jefferies.

Xenon Pharmaceuticals Inc (NASDAQ:XENE) Ratings Coverage

Among 5 analysts covering Xenon Pharmaceuticals (NASDAQ:XENE), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Xenon Pharmaceuticals has $20 highest and $5.0 lowest target. $12’s average target is 280.95% above currents $3.15 stock price. Xenon Pharmaceuticals had 14 analyst reports since August 11, 2015 according to SRatingsIntel. The stock of Xenon Pharmaceuticals Inc (NASDAQ:XENE) earned “Buy” rating by Canaccord Genuity on Tuesday, June 27. The rating was reinitiated by Jefferies with “Buy” on Monday, March 13. The stock has “Buy” rating by Guggenheim on Monday, September 26. The stock of Xenon Pharmaceuticals Inc (NASDAQ:XENE) earned “Sell” rating by Zacks on Wednesday, August 19. The firm has “Buy” rating by Jefferies given on Friday, August 4. As per Wednesday, September 2, the company rating was downgraded by Zacks. On Friday, October 30 the stock rating was reinitiated by Jefferies with “Buy”. The firm has “Buy” rating by Canaccord Genuity given on Tuesday, August 11. Jefferies maintained Xenon Pharmaceuticals Inc (NASDAQ:XENE) rating on Monday, September 11. Jefferies has “Buy” rating and $5.0 target. Jefferies maintained it with “Buy” rating and $800 target in Monday, June 12 report.

It closed at $3.15 lastly. It is down 39.94% since September 17, 2016 and is downtrending. It has underperformed by 56.64% the S&P500.

Investors wait Xenon Pharmaceuticals Inc (NASDAQ:XENE) to report on November, 2. its quarterly earnings Wall Street analysts expect $-0.07 earnings per share, up $0.44 or 86.27 % from last year’s $-0.51 same quarter earnings. Xenon Pharmaceuticals Inc’s Wall Street analysts see -82.93 % EPS growth, taking into account the $-0.41 EPS reproted in the previous quarter,

Xenon Pharmaceuticals Inc is a Canada clinical-stage biopharmaceutical company. The company has market cap of $56.70 million. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. It currently has negative earnings. The Company’s product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 and XEN1101.

More notable recent Xenon Pharmaceuticals Inc (NASDAQ:XENE) news were published by: Seekingalpha.com which released: “Xenon Pharmaceuticals’ (XENE) CEO Simon Pimstone on Q2 2017 Results – Earnings …” on August 06, 2017, also Globenewswire.com with their article: “Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with …” published on June 27, 2017, Benzinga.com published: “Mid-Day Market Update: Crude Oil Up Over 2%; Xenon Pharmaceuticals Shares Slide” on June 27, 2017. More interesting news about Xenon Pharmaceuticals Inc (NASDAQ:XENE) were released by: Globenewswire.com and their article: “Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second …” published on July 27, 2017 as well as Globenewswire.com‘s news article titled: “Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium …” with publication date: April 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: